Shenzhen Kangtai Biological Products Co.,Ltd. (300601.SZ) announced that the market authorization application for its self-developed influenza virus split vaccine has recently received an "Acceptance Notice" from the National Medical Products Administration. The influenza virus split vaccine covered by this accepted market authorization application is indicated for individuals aged 3 years and above. The vaccine can stimulate the body to produce immunity against influenza viruses and is intended for the prevention of influenza caused by vaccine-related strains of influenza viruses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments